Alternate Name(s):
REOPRO®
Classification:
Chimeric monoclonal antiplatelet antibody/glycoprotein IIb/IIIa-receptor inhibitor.
Original Date:
August 2005
Revised Date:
September 2011
Indications:
- RESTRICTED FOR USE IN CRITICAL CARE AREAS; CARDIOLOGY SHOULD BE CONSULTED.
- Experience in children limited. One study of 15 pediatric patients (Pediatrics Vol. 109 No. 1 Jan 2002 Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki Disease) used the same dosing guidelines as in adults for a 12 hour infusion
Reconstitution and Stability:
- Available as a 2 mg/mL injection
- Vial is stable 7 days refrigerated once punctured
- Diluted solutions (36 mcg/mL) stable 30 hours at room temperature
- DO NOT SHAKE
- Filter through a low protein-binding filter (0.2 or 0.22 micrometer)
Compatibility:
- Solutions Compatible: D5W, NS
- NO OTHER drugs should be administered with abciximab
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct | YES Infusion time: over at least 1 minute |
| IV Intermittent Infusion | NO |
| IV Continuous Infusion | YES |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Adults: 0.25 mg/kg loading dose
0.125 mcg/kg/min (maximum 10 mcg/min)
Potential hazards of parenteral administration:
- Anaphylaxis
- Thrombocytopenia, bleeding, hematoma (monitor potential bleeding sites)
- Hypotension, bradycardia
- Nausea, vomiting
Notes:
- Safety and efficacy of abciximab have been investigated with concomitant administration of aspirin and heparin
- Monitoring: clotting time, PT, aPTT, hemoglobin, hematocrit, platelet count